首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   566170篇
  免费   47719篇
  国内免费   19730篇
耳鼻咽喉   3869篇
儿科学   12438篇
妇产科学   7508篇
基础医学   85633篇
口腔科学   11007篇
临床医学   49511篇
内科学   87562篇
皮肤病学   7589篇
神经病学   38549篇
特种医学   13591篇
外国民族医学   166篇
外科学   47987篇
综合类   84606篇
一般理论   25篇
预防医学   33208篇
眼科学   10923篇
药学   62845篇
  193篇
中国医学   22257篇
肿瘤学   54152篇
  2023年   6945篇
  2022年   10398篇
  2021年   17495篇
  2020年   19339篇
  2019年   24000篇
  2018年   17319篇
  2017年   18749篇
  2016年   18754篇
  2015年   20456篇
  2014年   32322篇
  2013年   36678篇
  2012年   32732篇
  2011年   37666篇
  2010年   31571篇
  2009年   30543篇
  2008年   30383篇
  2007年   30764篇
  2006年   28023篇
  2005年   25335篇
  2004年   21762篇
  2003年   18916篇
  2002年   14977篇
  2001年   13806篇
  2000年   11414篇
  1999年   10030篇
  1998年   7586篇
  1997年   6948篇
  1996年   6153篇
  1995年   6197篇
  1994年   5501篇
  1993年   4584篇
  1992年   3952篇
  1991年   3450篇
  1990年   2892篇
  1989年   2504篇
  1988年   2297篇
  1987年   1857篇
  1986年   1615篇
  1985年   2524篇
  1984年   2571篇
  1983年   1755篇
  1982年   2005篇
  1981年   1637篇
  1980年   1440篇
  1979年   1191篇
  1978年   954篇
  1977年   753篇
  1976年   769篇
  1975年   604篇
  1974年   461篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.  相似文献   
3.
4.
5.
6.
7.

Background

Autoimmune diseases are associated with many cancers but there is a lack of population-based studies with different autoimmune diseases that have a long follow-up. This is also true of hepatobiliary cancers, which include hepatocellular cancer (HCC) and rarer entities of gallbladder cancer (GBC), intra- and extrahepatic cholangiocarcinoma (iCCA and eCCA), and ampullary cancer.

Methods

Diagnostic data on 43 autoimmune diseases were collected from the Swedish Inpatient Register from 1987 to 2018, and cancer data were derived from the national cancer registry from 1997 onward. Relative risks were expressed as standardized incidence ratios (SIRs).

Results

In a population of 13.6 million, 1.1 million autoimmune diseases were diagnosed and subsequent hepatobiliary cancer was diagnosed in 3191 patients (17.2% of cancers). SIRs for HCC were 2.73 (men) and 2.86 (women), 3.74/1.96 for iCCA, 2.65/1.37 for GBC, 2.38/1.64 for eCCA, and 1.80/1.85 for ampullary cancer. Significant associations between autoimmune disease and HCC were observed for 13 autoimmune diseases, with the highest risks being for autoimmune hepatitis (48.92/73.53, men/women) and primary biliary cirrhosis (38.03/54.48). GBC was increased after six autoimmune diseases, with high SIRs for ulcerative colitis (12.22/3.24) and men with Crohn disease (9.16). These autoimmune diseases were also associated with a high risk of iCCA, which had seven other associations, and eCCA, which had five other associations. Ampullary cancer occurrence was increased after four autoimmune diseases.

Conclusion

An autoimmune disease is a common precursor condition for hepatobiliary cancers. This calls for careful control of autoimmune disease symptoms in each patient and encouragement to practice a healthy lifestyle.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号